Menveo is a quadrivalent conjugated vaccine containing the Neisseria meningitidis serogroups A, C, Y and W-135. The presence of serum bactericidal antibodies protects against invasive meningococcal disease. Vaccination with Menveo leads to the production of bactericidal antibodies directed against the capsular polysaccharides of serogroups A, C, Y and W-135.
Menveo is specifically indicated for active immunization to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y and W-135. in persons 11 to 55 years of age.
Submit your review
Adverse events associated with the use of Menveo may include, but are not limited to, the following:
pain at the injection site
Menveo is supplied as a solution for intramuscular injection. Following reconstitution, Menveo should be administered as a single 0.5mL intramuscular injection, preferably into the deltoid muscle (upper arm).